



## OvaScience Advisor Receives the American Fertility Association's Visionary Award

November 4, 2013

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2013-- [OvaScience<sup>SM</sup>](#), (NASDAQ:OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Clinical Advisory Board member Alan Penzias, M.D., has been honored by The American Fertility Association (AFA) with The Joyce M. Vargyas, M.D. Visionary Award. Dr. Penzias will receive his award on November 4, 2013 during The American Fertility Association's annual gala, *Illuminations*, a benefit honoring individuals who have made extraordinary contributions to the fertility field.

"Dr. Penzias is committed to patients and has made tremendous contributions to the field of fertility and reproductive medicine," said Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience. "He has been instrumental in guiding the development of new technologies that may lead to better infertility treatments for the millions of people who want to have their own families."

The AFA is a national, not-for-profit charitable organization committed to helping people create their families of choice by providing leading-edge outreach programs and timely educational information.

### About OvaScience

OvaScience (NASDAQ: OVAS) is a life sciences company focused on the discovery, development and commercialization of new treatments for infertility. The Company's patented technology is based on the discovery of egg precursor cells (EggPC<sup>SM</sup>), which are found in the ovaries. By applying proprietary technology to identify and purify EggPCs, OvaScience is developing potential next generation *in vitro* fertilization (IVF) technologies. The Company currently has two product candidates in development: OvaTure<sup>SM</sup>, which seeks to create mature fertilizable eggs from a woman's own EggPCs without the need for hormone injections, and AUGMENT<sup>SM</sup>, which aims to improve egg quality and increase the success of IVF. OvaScience's team of scientists, physicians and advisers includes recognized leaders in the field of reproductive medicine. For more information, please visit [www.ovascience.com](http://www.ovascience.com) and connect with us on [Twitter](#) and [Facebook](#).

### Forward-Looking Statements

*This press release includes forward-looking statements about the prospects for the Company's technology in addressing female infertility, the Company's strategy, future plans and prospects, including statements regarding the planned discovery, development and commercialization of the Company's product candidates. Any statements in this release about our strategy, plans, prospects and future expectations, financial position and operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "aim," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: our expectations regarding the regulatory approvals required for AUGMENT; the science underlying our two product candidates (AUGMENT and OvaTure), which is unproven; our ability to obtain, maintain and protect intellectual property utilized by our products; our ability to obtain additional funding to support our activities; our dependence on third parties; the successful development of, and ability to obtain regulatory approval for, our product candidates; our ability to commercialize our product candidates, including AUGMENT, on the timeline we expect, if at all; competition from others; and our short operating history; as well as those risks more fully discussed in the "Risk Factors" section of our most recently filed Quarterly Report on Form 10-Q or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.*

Source: OvaScience

OvaScience, Inc.  
Theresa McNeely, 617-299-7356  
EVP, Strategic Corporate Communications  
[tmcneely@ovascience.com](mailto:tmcneely@ovascience.com)